AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

StrataMGT in the Reduction of Vulvar Lichen Sclerosus (LS) Symptoms

RecruitingPhase 1Ages 18 Years - anyFemaleAndrew T. Goldstein, MD
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study is designed to evaluate the efficacy and safety of StrataMGT for the management of vulvar lichen sclerosus symptoms.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Female, 18 years or older. * With a diagnosis of biopsy proven vulvar lichen sclerosus. * Signed written informed consent. * Willingness and ability to comply with the study requirements. * Subject must have a score of 10 or greater in the VQLI at screening. * Must be on a stable regimen of topical corticosteroids or topical calcineurin inhibitor for at least 2 months prior to the screening visit. * Women currently on a stable regimen of intravaginal estrogen therapy for at least 2 months may remain on the estrogen therapy throughout the study. * Women currently using topical estrogen therapy on the vulva must stop two weeks prior to enrolling in the study. * Women must have a culture negative for candidiasis or bacterial vaginosis at screening. Exclusion Criteria: * Who are immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich Syndrome) or have an uncontrolled malignant disease. * Who suffer from a topical or systemic infections (bacterial, viral or fungal) at the time of screening. Subjects who screen positive for either candidiasis or bacterial vaginosis at the screening visit may be treated and retested and may participate if the confirmatory test after treatment is negative. Any vulvovaginal infections during their participation in the study will be considered an adverse event. The subject will then stop the study IP and will be treated for the infection and may resume use of the IP 3 days after the last dose of medication for the infection. They will be discontinued from the study if they have two infections during the study. * Who have been diagnosed with lichen planus, psoriasis, intraepithelial neoplasia, or carcinoma of the vulva. * Who had received an investigational drug within four weeks prior to the study or who intend to use other investigational drugs during the course of this study. * Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study. * Who have a history of substance abuse or any factor, which limits the subject's ability to cooperate with the study procedures. * Who are uncooperative, known to miss appointments (according to subjects' records) and are unlikely to follow medical instructions or are not willing to attend regularly scheduled visits.
๐Ÿ’Š

What it tests

  • StrataMGT
  • Placebo
๐Ÿ“

Where

3 sites
Centers for Vulvovaginal Disorders, DC
Washington D.C., United States
Centers for Vulvovaginal Disorders, FL
Tampa, United States
Centers for Vulvovaginal Disorders, NY
New York, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy